Library

Insights

From covariates to confounding factors: the danger of having too many covariates

Clinical trials typically evaluate efficacy of experimental therapies in heterogeneous patient populations, as patient characteristics vary significantly. These patient characteristics might be prognostic factors that ultimately induce…

Read More
Insights

Regulatory Guidelines for the Use of Baseline Covariates to Increase Clinical Trial Study Power

Clinical trials data analyses can employ baseline covariates to control for factors that may impact measurement of outcomes – particularly to describe individual patient characteristics that may…

Read More
Insights

Does the placebo response need to be considered in clinical trials for COVID-19 vaccines and treatments?

The search for drugs to treat and prevent SARS-CoV-2 infection is ongoing, with more than 1200 drugs in the pipeline and more 3,200 clinical trials planned or…

Read More
Insights

Frequently asked questions about COV-IQ

This webinar aimed to explain the impact of COVID-19 crisis on patient behavior in ongoing clinical trials, introduce the application of COV-IQ technology and describe how it…

Read More
Insights

Pandemic Stress Will Affect Clinical Trial Response: What Can Industry Do?

As one might expect, the life changes are a source of stress, and the data supports this assertion. In fact, a recent analysis by Express Scripts also…

Read More
Insights

The Placebo response in drug development Part 3: Parkinson’s disease

Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disease characterized by both motor and non-motor features. The disease has a significant clinical impact on patients, families, and…

Read More